---
phase: 115
phase_name: "Support Matrix Boundaries"
status: passed
verified_at: "2026-06-01"
requirements: [SUPPORT-01, SUPPORT-02, SUPPORT-03, SUPPORT-04]
---

# Phase 115 Verification

## Result

Status: passed

Phase 115 delivers the planned support-matrix boundary update. Public docs now
separate RDNA 4 engineering-prerelease evidence, Docker/container user-space
evidence, MI300X/CDNA3 deferred full-suite validation, and unavailable CDNA4
validation.

## Checks Run

```bash
UV_CACHE_DIR=/tmp/uv-cache uv run pytest tests/sol_execbench/test_research_release_docs.py tests/sol_execbench/test_public_contract_guardrails.py tests/sol_execbench/test_release_candidate_validation.py -q
```

Result: `75 passed in 11.51s`.

## Goal-Backward Assessment

- SUPPORT-01: Passed. `docs/rocm.md` identifies RDNA 4 engineering-prerelease
  evidence without upgrading it to full paper validation or broader hardware
  validation.
- SUPPORT-02: Passed. `docs/rocm.md`, `docs/CLAIMS.md`, and
  `docs/release_candidate_validation.md` keep Docker/container ROCm user-space
  evidence distinct from native-host validation.
- SUPPORT-03: Passed. Public docs state MI300X is the concrete CDNA3 hardware
  target (`gfx942`) and full-suite MI300X/CDNA3 validation remains deferred
  without complete real-hardware evidence.
- SUPPORT-04: Passed. Public docs state CDNA4 validation is unavailable because
  suitable hardware is not currently accessible.

## Residual Risk

No runtime or hardware validation was added in this phase. That is intentional:
the phase updates interpretation boundaries and CPU-safe documentation
guardrails only.
